Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M212,932Revenue $M49,605Net Margin (%)18.7Altman Z-Score2.8
Enterprise Value $M221,460EPS $1.4Operating Margin %25.9Piotroski F-Score6
P/E(ttm)24.3Beneish M-Score-2.7Pre-tax Margin (%)25.4Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %2.6Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %4.4Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow17.0y-y EBITDA Growth Rate %-9.8ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %3.1PEG5.4ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,158ROIC % (ttm)12.1Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKahn Brothers 2015-03-31 Reduce-0.39%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 3.83%1,811,016
PFEJames Barrow 2015-03-31 Reduce-0.32%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 12.24%55,080,222
PFENWQ Managers 2015-03-31 Reduce-0.16%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 6.64%5,927,532
PFEJoel Greenblatt 2015-03-31 Add0.15%$31.16 - $35.05
($33.51)
$ 34.583%Add 38.84%1,972,788
PFECharles Brandes 2015-03-31 Reduce-0.07%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 2.37%6,123,536
PFEDavid Dreman 2015-03-31 Add0.03%$31.16 - $35.05
($33.51)
$ 34.583%Add 70.38%25,202
PFEMario Gabelli 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 5.80%896,431
PFEDodge & Cox 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 34.583%Reduce 0.89%46,776,959
PFERichard Pzena 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.583%Reduce 0.50%2,159,618
PFEFirst Eagle Investment 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.583%Reduce 0.12%5,266,820
PFEJohn Keeley 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.583%Reduce 1.27%98,689
PFEKen Fisher 2015-03-31 Add$31.16 - $35.05
($33.51)
$ 34.583%Add 0.04%31,208,271
PFEKahn Brothers 2014-12-31 Reduce-0.49%$27.7 - $32.09
($30.23)
$ 34.5814%Reduce 5.14%1,883,217
PFEFirst Eagle Investment 2014-12-31 Add0.39%$27.7 - $32.09
($30.23)
$ 34.5814%Add 3786.85%5,272,943
PFERichard Pzena 2014-12-31 Buy 0.36%$27.7 - $32.09
($30.23)
$ 34.5814%New holding2,170,568
PFEVanguard Health Care Fund 2014-12-31 Add0.32%$27.7 - $32.09
($30.23)
$ 34.5814%Add 29.88%19,395,622
PFEMichael Price 2014-12-31 Sold Out -0.17%$27.7 - $32.09
($30.26)
$ 34.5814%Sold Out0
PFEKahn Brothers 2014-09-30 Reduce-0.59%$28.04 - $30.96
($29.58)
$ 34.5817%Reduce 6.56%1,985,161
PFEMichael Price 2014-09-30 Reduce-0.22%$28.04 - $30.96
($29.58)
$ 34.5817%Reduce 56.02%47,100
PFEFirst Eagle Investment 2014-09-30 Reduce-0.16%$28.04 - $30.96
($29.58)
$ 34.5817%Reduce 94.11%135,661
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$342.21view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.620.38view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.460.84view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.730.06view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-0.29view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.231.52view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.31.31view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-10Sell9,000$33.782.87view
MADDALUNA ANTHONY JExecutive Vice President 2014-12-08Sell6,500$328.59view
HILL CHARLES HExecutive Vice President 2014-11-10Sell8,285$30.1815.14view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
      Ken Fisher Adds to His Pfizer Position May 27 2015 
      Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
      Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
      Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer May 22 2015 
      Joel Greenblatt Increases Position in Pfizer May 17 2015 
      Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
      Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
      Endo International Posts Upbeat Q1 Results May 13 2015 
      Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 

      More From Other Websites
      AstraZeneca CEO: Transforming cancer treatments Jun 01 2015
      12:19 am Pfizer announces palbociclib more than doubled progression-free survival in Phase 3 trial... May 31 2015
      Billionaire Cliff Asness’ Long Term Holdings May 31 2015
      Pfizer's Ibrance drug slows progression of breast cancer May 30 2015
      Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for... May 30 2015
      Pfizer's Ibrance drug slows progression of breast cancer May 30 2015
      Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for... May 30 2015
      Pfizer's Ibrance drug slows progression of breast cancer May 30 2015
      Viagra Maker Pfizer Keeps Boosting Dividends May 29 2015
      BMY hit on disappointing drug trial May 29 2015
      Buying into biotech: 5 trades on 3 stocks May 29 2015
      Stocks close lower but post gains for May; data, Greece weigh May 29 2015
      Pfizer (PFE) Stock Gaining on Rare Lung Disorder Treatment Approval May 29 2015
      At ASCO: Bristol, Merck Drugs Shrink Several Tumor Types May 29 2015
      Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis... May 29 2015
      Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis... May 29 2015
      Pfizer Gets OK On Drug For Rare Lung Disorder May 29 2015
      French biotech firm Cellectis jumps on takeover hopes May 29 2015
      French biotech firm Cellectis jumps on takeover hopes May 29 2015
      French drugmaker Cellectis in sale talks -FT May 28 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      SEENSCO
      ReplySEENSCO - 11 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK